# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Wants to understand a new diagnosis of prostate cancer after a rising PSA, and what treatment would mean at his age and with his commitments **S**
- Wants to keep his travel and public work going during treatment **S**

## Your goals

- Reach an informed, shared decision on treatment after hearing every reasonable option, including observation. Target: 2001-04-14. Recorded outcome: Radiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation. **S**
- Complete six months of androgen deprivation and the course of radiotherapy with side effects managed. Target: 2001-10-27. Recorded outcome: Two leuprolide depots and 37 fractions completed; testosterone castrate on treatment; mild hot flashes and urinary frequency, managed. **S**
- Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise. Target: 2001-07-14. Recorded outcome: Femoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking daily. **S**
- PSA falling after radiotherapy, with a written surveillance plan. Target: 2001-10-27. Recorded outcome: PSA 0.4 ng/mL six weeks after radiotherapy; PSA every six months planned. **S**

## What we agreed to do

- Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivation. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022) **S**
- Staging for unfavorable intermediate-risk disease with PSMA PET/CT. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
- Treatment chosen through shared decision-making: image-guided external beam radiotherapy to the prostate with six months of androgen deprivation (leuprolide, with bicalutamide for the first four weeks). Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022) **S**
- Androgen deprivation monitoring: testosterone, PSA, blood pressure, glucose and lipids, DXA at baseline and every one to two years, vitamin D and calcium, hot flashes, mood, and cognition. Guideline: Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
- After radiotherapy: PSA every six months for five years, then yearly, with recurrence defined as a rise of 2 ng/mL above the nadir (Phoenix); urinary and bowel symptoms at every visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**

## Follow-up

- 2001-03-10: First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral **S**
- 2001-04-14: Five-week follow-up with radiation oncology consultation: staging result, shared decision on treatment, start of androgen deprivation, and bone density **S**
- 2001-06-09: Subsequent annual wellness visit **S**
- 2001-07-14: Three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effects **S**
- 2001-10-27: Follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance plan **S**

This teaching document does not replace care from a qualified clinician.
